BN-02 blocks degradation and triggers restoration of OA cartilage.
High unmet medical need
Osteoarthritis (OA) is the most common chronic condition of the joints, affecting approximately 27 million Americans.
Globally as of 2010, approximately 250 million people had osteoarthritis of the knee (3.6% of the population). One in two adults will develop symptoms of knee OA during their lives and the disease population is growing faster than the general population.
Currently, no treatment is available to counteract disease progression. Patients only have access to symptomatic treatments which are often associated with side effects. Progressive cartilage destruction leads to advanced stages of the disease, where joint replacement still remains the only option for numerous patients.